INTRODUCTION
Orofacial pain treatments remain an important consideration in dental care and patient management. Patients often evaluate a clinician's ability by their success or failure in pain control. Dental pain management requires a multifactorial approach that includes a combination of good treatment procedures and the use of appropriate analgesics 12 .
The majority of drugs used to manage pain in (NSAIDs) and opioid analgesics 10 . Opioid analgesics are controlled substances and have many serious adverse side effects such as drug abuse, nausea, and vomiting 3 . Thus, most acute dental pain can be managed with the proper NSAID. However, due to the problems associated with the long term use of NSAIDs, which may be associated with renal diseases 17 . Thus, it is necessary to discover new drugs and new target molecules to relieve severe dental pain.
It is well known that serotonin plays a crucial role in the regulation of pain via its interaction with 5-HT receptors 2 . Previous studies have reported roles for 5-HT1A, 5-HT2, and 5-HT3 receptors in pain regulation 9, 14, 16 . The 5-HT7 receptor is the most studies have provided evidence that 5-HT7 receptor agonists produce antinociceptive effects in a variety a recent study, Yang, et al. 20 (2014) indicate that 5-HT7 receptors are functionally expressed in a subpopulation of the substantia gelatinosa of the trigeminal subnucleus caudalis, which receives and processes orofacial nociceptive inputs. To our of 5-HT7 receptor agonists on orofacial pain. In this study, we investigated the effects of selective 5-HT7 receptor agonists, LP 44 and LP 211, on orofacial pain using a formalin model in mice.
MATERIAL AND METHODS

Selection of the experimental group
Experiments were performed in the Drug Research and Development Laboratory of Pharmacology Department. Female Balb-C (25-32 g) mice were used. Mice were housed in a wellventilated room at 22±2°C under a 12 h light: 12 h dark cycle and with free access to food and water. The experimental group consisted of 6-8 mice. Nociception was evaluated by using orofacial formalin test. Each of the subjects were allowed to separately provide adaptation within 30 min in the observation room in which a 30x30x30 cm Plexiglas box was placed with mirrors with a 45 degree angle to see unobstructed views of the orofacial region. The protocol was approved by the Animal Care and Use Committee.
Drugs
Selective 5-HT7 receptor agonists, LP 44 and LP 211, were used for this study. While LP 44 was dissolved in distilled water, LP 211 was dissolved in 5% dimethyl sulfoxide (DMSO). LP 44 and LP 211 (1, 5, and 10 mg/kg) were given intraperitoneally (i.p.) in a volume of 5 ml/kg, 30 minutes prior to the formalin injection. Vehicle was given to the control groups.
Orofacial formalin test and the assessment of antinociceptive effects
Orofacial nociception was evaluated using formalin as previously described 11 . A bolus of 4% formalin (10 μl) was subcutaneously injected into the upper lip of mice just lateral to the nose. The time of the paw strokes directed to the injection area, called face rubbing, was recorded over a 30-minute period, which was divided into 10 blocks of 3 min each, while the mice were in Plexiglas cages. In our study, cumulative data collected between 0 and 9 min post-formalin injection were grouped as phase 1 (0-9 min), whereas phase 2 was composed of data collected between 12 and 30 min post-formalin injection (the late phase).
Statistical analysis
Data are expressed as means±standard error of the mean (SEM) for each group. GraphPad Prism 4 software (GraphPad Software, San Diego California, USA) was used for the statistical analyses. In vehicle treatment on face rubbing responses were evaluated by two-way repeated measure analysis of variance. Next, the averages of the period (0-9 min for Phase I and 12-30 min for Phase II) were calculated in each animals (bar graphs) and one way ANOVA were used to compare groups. A as the criterion for progressing to post-hoc testing. The Bonferroni post-hoc test was used to compare as p<0.05.
RESULTS
Consistent with previous studies, following the formalin injection, a typical biphasic time course activity (Phase I) was observed. This was followed by a 3-minute quiescent period. Then, a second, prolonged (12-30 min) tonic phase (Phase II) was observed ( Figure 1A ). The mean of the total face rubbing times were 96.29±1.6 seconds and 61.33±2.41 seconds during Phase I (0-9 min) and Phase II (12-30 min), respectively ( Figures  1B and 1C) .
The two-way repeated measures of ANOVA analysis indicated that systemic administration of LP induced by formalin injection (F 3,392 =601.1, P<0.0001) ( Figure 1A ). While 1 mg/kg was ineffective, LP 44 doses of 5 and 10 mg/kg profoundly reduced face rubbing times at 3 and 6 min in Phase I ( Figure 1A ). Similar to Phase I, LP 44 at doses induced face rubbing responses at 15, 18, 21, and 24 min in Phase II ( Figure 1A ). The mean of the total face rubbing times in Phase I, after LP 44 injection at the doses of 5 and 10 mg/kg, were s (both p<0.001), respectively, in Phase I, which rubbing times during Phase II to 37.2±2.7 and 17.88±2.94 s (both p<0.001), respectively, when compared with 5% DMSO-treated vehicle group ( Figure 2C ).
DISCUSSION
In this study, we have demonstrated that selective 5-HT7 receptor agonists elicit analgesic studies implying a role of 5-HT7 receptors in pain pathways.
The pathologic states of the teeth and the related structure induced acute orofacial pain is one of the most common pain, and it is well known that the orofacial region is heavily innervated by the trigeminal nerve. The orofacial formalin test is a recognized model of animal model of nociception related to trigeminal pain 13 . Formalin, as an electrophile irritant, induces tissue injury following its intracutaneous injection accompanied with prototypical a biphasic pattern of pain response serotonin receptor subtype. Our previous studies and other studies show that 5-HT7 receptor play a key role both in endogenous pain control and exogenously administered opioid and non-opioid analgesics drug action 8, 19, 21 . There are very few studies that examine the analgesic effects of selective 5-HT7 receptor agonist. Brenchat, et al. , as expected, we found that LP 44 and LP 211 reduced the nociceptive behavior in both phases of the orofacial formalin test. As CNSpenetrant drugs, after systemic administration, LP 44 and LP 211 can access peripheral, spinal, and supraspinal sites 15 . Thus, in the present study, the site of action underlying analgesic effects of 5-HT7 agonist is unclear. Several studies demonstrated the involvement of descending serotonergic systems in modulating the orofacial nociception 7 . Interestingly, we reported the special important role of 5-HT7 in the descending pain inhibitory pathways 7, 21 . Neuroanatomical studies demonstrate the existence of 5-HT7 receptors in the substantia gelatinosa of the trigeminal subnucleus caudalis, which play a critical role in mediating orofacial nociception. Thus, it is possible to speculate that the antinociceptive action of LP 44 and LP 211 may be attributed to the activation of 5-HT7 receptors in the substantia gelatinosa neurons of the trigeminal nerve.
Nevertheless, we cannot exclude the possibility that 5HT2A receptors contribute to antinociception in the other brain areas and/or in the periphery. Further studies are needed to clarify the exact mechanism of analgesic action of 5-HT7 receptor agonist on orofacial pain.
CONCLUSION
In conclusion, our results suggest that targeting 5-HT7 receptor might provide a new therapeutic tool for the treatment of orofacial painful conditions. should be tested in human orofacial pain models.
